Skip to Content
Merck
All Photos(2)

Documents

SML3972

Sigma-Aldrich

Azeliragon

≥98% (HPLC)

Synonym(s):

PF-04494700, PF04494700, 3-(4-{2-Butyl-1-[4-(4-chlorophenoxy)-phenyl]-1H-imidazole-4-yl}-phenoxy)-propyl]-diethylamine 1, 3-[4-[2-Butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine), PF 04494700, TTP 488, TTP-488, TTP488

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C32H38ClN3O2
CAS Number:
Molecular Weight:
532.12
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

, White to light brown

solubility

DMSO: 2 mg/mL, clear

storage temp.

room temp

Biochem/physiol Actions

Orally active, brain-penetrant, selective receptor for advanced glycation end products (RAGE) antagonist in vitro and in vivo.


Azeliragon (PF-04494700; TTP488) is an orally active, brain-penetrant, selective receptor for advanced glycation end products (RAGE) antagonist (Kd = 12.7 nM using sRAGE; little affinity toward >100 receptors/transporters) that blocks known RAGE ligands binding (S100b, amphoterin, carboxymethyl-lysine, and Aβ1-42). Azeliragon (0.3-3 mg/kg/day p.o.) reduces brain amyloid (Aβ1-40 & Aβ1-42) and inflammatory markers (TNF-α, TGF-β and IL-1), while increases plasma Aβ in tgAPPSWE/LON mice, a mouse model with Swedish and London mutations that over-express human APP.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective
Journal of Medicinal Chemistry, 60(17), 7213-7232 (2017)
Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer's Disease
The journal of prevention of Alzheimer's disease, 5(2), 149-154 (2018)
Melinda Magna et al.
NPJ breast cancer, 9(1), 59-59 (2023-07-14)
Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic cancer subtype, which is generally untreatable once it metastasizes. We hypothesized that interfering with the Receptor for Advanced Glycation End-products (RAGE) signaling with the small molecule RAGE inhibitors (TTP488/Azeliragon and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service